{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:14:23Z","timestamp":1779938063579,"version":"3.53.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/00478"],"award-info":[{"award-number":["PI14\/00478"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/0797"],"award-info":[{"award-number":["PI15\/0797"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bpg.2018.06.005","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T06:29:05Z","timestamp":1528957745000},"page":"63-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Primary biliary cholangitis and bone disease"],"prefix":"10.1016","volume":"34-35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-9687","authenticated-orcid":false,"given":"Albert","family":"Par\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Gua\u00f1abens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1053\/j.gastro.2015.08.031","article-title":"Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'","volume":"149","author":"Beuers","year":"2015","journal-title":"Gastroenterology"},{"issue":"10003","key":"10.1016\/j.bpg.2018.06.005_bib2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.005_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1089-3261(03)00100-4","article-title":"Natural history of primary biliary cirrhosis","volume":"7","author":"Pares","year":"2003","journal-title":"Clin Liver Dis"},{"issue":"8014","key":"10.1016\/j.bpg.2018.06.005_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(77)92167-5","article-title":"Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis","volume":"1","author":"Compston","year":"1977","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.005_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cld.2008.02.005","article-title":"Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment","volume":"12","author":"Pares","year":"2008","journal-title":"Clin Liver Dis"},{"issue":"12","key":"10.1016\/j.bpg.2018.06.005_bib6","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1172\/JCI27071","article-title":"Pathogenesis of osteoporosis: concepts, conflicts, and prospects","volume":"115","author":"Raisz","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/hep.1840070127","article-title":"Low bone turnover state in primary biliary cirrhosis","volume":"7","author":"Stellon","year":"1987","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.005_bib8","first-page":"1356","article-title":"Factors influencing the development of metabolic bone disease in primary biliary cirrhosis","volume":"85","author":"Guanabens","year":"1990","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.bpg.2018.06.005_bib9","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1359\/jbmr.2003.18.12.2190","article-title":"Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease","volume":"18","author":"Guichelaar","year":"2003","journal-title":"J\u00a0Bone Miner Res: Official J Am Soc Bone Miner Res"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.005_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1359\/jbmr.1998.13.4.731","article-title":"Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis","volume":"13","author":"Guanabens","year":"1998","journal-title":"J\u00a0Bone Miner Res.: Official J Am Soc Bone Miner Res"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.005_bib11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.510280315","article-title":"Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis","volume":"28","author":"Gallego-Rojo","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0168-8278(98)80211-0","article-title":"Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment","volume":"28","author":"Cemborain","year":"1998","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2018.06.005_bib13","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1359\/jbmr.080313","article-title":"Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation","volume":"23","author":"Kawelke","year":"2008","journal-title":"J\u00a0Bone Miner Res.: Official J Am Soc Bone Miner Res"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib14","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1172\/JCI117959","article-title":"Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice","volume":"95","author":"Janes","year":"1995","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2362.2009.02230.x","article-title":"Lithocholic acid downregulates vitamin D effects in human osteoblasts","volume":"40","author":"Ruiz-Gaspa","year":"2010","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib16","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/hep.24605","article-title":"Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases","volume":"54","author":"Ruiz-Gaspa","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.005_bib17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/liv.12153","article-title":"Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells","volume":"33","author":"Dubreuil","year":"2013","journal-title":"Liver Int: Official J Inter Assoc Study Liver"},{"issue":"12","key":"10.1016\/j.bpg.2018.06.005_bib18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/eci.12355","article-title":"Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis","volume":"44","author":"Ruiz-Gaspa","year":"2014","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.005_bib19","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/jbmr.2845","article-title":"Sclerostin expression in bile ducts of patients with chronic cholestasis may influence the bone disease in primary biliary cirrhosis","volume":"31","author":"Guanabens","year":"2016","journal-title":"J\u00a0Bone Miner Res.: Official J. Am. Soc. Bone Miner Res."},{"issue":"4","key":"10.1016\/j.bpg.2018.06.005_bib20","first-page":"409","article-title":"Vitamin K and bone health","volume":"16","author":"Hamidi","year":"2013","journal-title":"J\u00a0Bone Miner Res: Official J Am Soc Bone Miner Res"},{"issue":"12","key":"10.1016\/j.bpg.2018.06.005_bib21","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/archinte.166.12.1256","article-title":"Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials","volume":"166","author":"Cockayne","year":"2006","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.005_bib22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/lt.20874","article-title":"Bone mineral density before and after OLT: long-term follow-up and predictive factors","volume":"12","author":"Guichelaar","year":"2006","journal-title":"Liver Transplant: Official Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/8756-3282(93)90310-7","article-title":"Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis","volume":"14","author":"Hodgson","year":"1993","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.005_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000171456","article-title":"Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management","volume":"12","author":"McCaughan","year":"1994","journal-title":"Dig Dis"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.005_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0168-8278(02)00435-X","article-title":"High serum osteoprotegerin and low RANKL in primary biliary cirrhosis","volume":"38","author":"Szalay","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.005_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00774-009-0042-1","article-title":"High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue","volume":"27","author":"Guanabens","year":"2009","journal-title":"J\u00a0Bone Miner Metabol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jhep.2005.05.034","article-title":"The RANKL\/OPG system and bone mineral density in patients with chronic liver disease","volume":"43","author":"Moschen","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0016-5085(00)70423-9","article-title":"Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis","volume":"118","author":"Springer","year":"2000","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.005_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/jhep.2001.22758","article-title":"Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis","volume":"33","author":"Pares","year":"2001","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.bpg.2018.06.005_bib30","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/01.meg.0000108364.41221.d0","article-title":"Insulin-like growth factor I gene microsatellite repeat, collagen type Ialpha1 gene Sp1 polymorphism, and bone disease in primary biliary cirrhosis","volume":"16","author":"Lakatos","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2018.06.005_bib31","doi-asserted-by":"crossref","first-page":"19877","DOI":"10.1038\/srep19877","article-title":"A\u00a0common variant in CLDN14 is associated with primary biliary cirrhosis and bone mineral density","volume":"6","author":"Tang","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.005_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00042737-200503000-00009","article-title":"Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis","volume":"17","author":"Pares","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1 Pt 1","key":"10.1016\/j.bpg.2018.06.005_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0016-5085(82)80299-0","article-title":"25-Hydroxyvitamin D3 treatment of bone disease in primary biliary cirrhosis","volume":"83","author":"Arnaud","year":"1982","journal-title":"Gastroenterology"},{"issue":"1 Pt 1","key":"10.1016\/j.bpg.2018.06.005_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0016-5085(82)80291-6","article-title":"Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment","volume":"83","author":"Matloff","year":"1982","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840040101","article-title":"Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia","volume":"4","author":"Cuthbert","year":"1984","journal-title":"Hepatology"},{"issue":"1 Pt 1","key":"10.1016\/j.bpg.2018.06.005_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0016-5085(82)80292-8","article-title":"Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D","volume":"83","author":"Herlong","year":"1982","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-103-6-855","article-title":"Bone loss and reduced osteoblast function in primary biliary cirrhosis","volume":"103","author":"Hodgson","year":"1985","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.005_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.1840100405","article-title":"A\u00a0pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss","volume":"10","author":"Mitchison","year":"1989","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.005_bib39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","article-title":"Bone disease in primary biliary cirrhosis: independent indicators and rate of progression","volume":"35","author":"Menon","year":"2001","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0168-8278(94)80132-0","article-title":"Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis","volume":"21","author":"Guanabens","year":"1994","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.005_bib41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2004.11.035","article-title":"Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis","volume":"42","author":"Guanabens","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.005_bib42","first-page":"389","article-title":"Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?","volume":"21","author":"Lindor","year":"1995","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.005_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00042737-199903000-00018","article-title":"Non-invasive assessment of bone density in primary biliary cirrhosis","volume":"11","author":"Pereira","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.005_bib44","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/gut.49.2.282","article-title":"Osteoporosis in primary biliary cirrhosis revisited","volume":"49","author":"Newton","year":"2001","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.005_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1297-319X(02)00364-0","article-title":"Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease","volume":"69","author":"Le Gars","year":"2002","journal-title":"Joint, bone, spine: revue du rhumatisme"},{"issue":"4 Pt 1","key":"10.1016\/j.bpg.2018.06.005_bib46","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/jhep.2002.36357","article-title":"Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry","volume":"36","author":"Guichelaar","year":"2002","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.005_bib47","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","article-title":"Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis","volume":"138","author":"Guanabens","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.005_bib48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1590-8658(03)00078-1","article-title":"Osteoporosis: still a typical complication of primary biliary cirrhosis?","volume":"35","author":"Solerio","year":"2003","journal-title":"Digest Liver Dis: Official J Italian Soc Gastroenterol Ital. Assoc Study of the Liver"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.005_bib49","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/jgh.13746","article-title":"Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis","volume":"32","author":"Seki","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib50","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0168-8278(00)80118-X","article-title":"Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial","volume":"33","author":"Lindor","year":"2000","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib51","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2006.09.012","article-title":"Fracture risk in people with primary biliary cirrhosis: a population-based cohort study","volume":"131","author":"Solaymani-Dodaran","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2018.06.005_bib52","first-page":"1","article-title":"Report of a WHO study group","volume":"843","author":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","year":"1994","journal-title":"World Health Organization technical report series"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.005_bib53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2006.06.007","article-title":"Treatment of bone disorders in liver disease","volume":"45","author":"Pares","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.005_bib54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s005350050250","article-title":"Calcitriol for bone loss in patients with primary biliary cirrhosis","volume":"34","author":"Shiomi","year":"1999","journal-title":"J\u00a0Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.005_bib55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0168-8278(92)90066-X","article-title":"Sodium fluoride prevents bone loss in primary biliary cirrhosis","volume":"15","author":"Guanabens","year":"1992","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.abb.2010.05.030","article-title":"Liver and bone","volume":"503","author":"Guanabens","year":"2010","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0016-5085(97)70098-2","article-title":"Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years","volume":"113","author":"Guanabens","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.005_bib58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0168-8278(97)80048-7","article-title":"Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study","volume":"26","author":"Wolfhagen","year":"1997","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.005_bib59","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","author":"Guanabens","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.005_bib60","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial","volume":"42","author":"Zein","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib61","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hep.26466","article-title":"Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis","volume":"58","author":"Guanabens","year":"2013","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.005_bib62","first-page":"S279","article-title":"Alendronate 70 mg once-weekly is more effective and has a better tolerability than alendronate 10 mg daily in the treatment of osteopenia aassociated with primary biliary cirrhosis","volume":"20","author":"Guanabens","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.005_bib63","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MJT.0b013e3181d7e1d3","article-title":"Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis","volume":"18","author":"Treeprasertsuk","year":"2011","journal-title":"Am J Therapeut"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib64","first-page":"47","article-title":"Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment","volume":"89","author":"Crippin","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.005_bib65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1478-3231.1999.tb00034.x","article-title":"Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis","volume":"19","author":"Olsson","year":"1999","journal-title":"Liver"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.005_bib66","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1572-0241.2003.07341.x","article-title":"Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis","volume":"98","author":"Menon","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2796.2004.01342.x","article-title":"An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis","volume":"256","author":"Ormarsdottir","year":"2004","journal-title":"J\u00a0Intern Med"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.005_bib68","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10620-006-8015-x","article-title":"Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen\/progestin","volume":"51","author":"Boone","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.005_bib69","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2036.2004.01890.x","article-title":"Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial","volume":"19","author":"Pereira","year":"2004","journal-title":"Aliment Pharmacol Therapeut"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.005_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1478-3231.2005.01026.x","article-title":"Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study","volume":"25","author":"Levy","year":"2005","journal-title":"Liver Int: Official J Int Association for the Study of the Liver"},{"key":"10.1016\/j.bpg.2018.06.005_bib71","first-page":"201A","article-title":"Efficacy of denosumab on progression of osteoporosis in autoimmune liver diseases","volume":"64","author":"Ikejima","year":"2016","journal-title":"Hepatology"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691818300052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691818300052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:01:18Z","timestamp":1761498078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691818300052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":71,"alternative-id":["S1521691818300052"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2018.06.005","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary biliary cholangitis and bone disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2018.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}